- Home
- LPCN
LPCN
Lipocine Inc.
as 07-26-2024 4:00pm EST
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 36.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 29.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.31 - $11.79 | Next Earning Date: | 08-08-2024 |
| Revenue: | $4,711,366 | Revenue Growth: | 748.91% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 81.58% |
Latest Lipocine Inc. News
LPCN Breaking Stock News: Dive into LPCN Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
PR Newswire
2 months ago
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
Zacks
2 months ago
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks
2 months ago
Here's Why Momentum in Lipocine (LPCN) Should Keep going
PR Newswire
3 months ago
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Associated Press Finance
3 months ago
Lipocine: Q1 Earnings Snapshot
PR Newswire
3 months ago
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
PR Newswire
3 months ago
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Compare LPCN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LPCN Lipocine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.